Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 11

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 11
---
 early termination in certain circumstances.

June 2025 Private Placement

In
June 2025, we completed a private placement, pursuant to which we sold and issued to certain investors, including our Chief Executive
Officer, (i) convertible notes in the aggregate principal amount of approximately $5.7 million, which automatically converted into 501,566
shares of our common stock at a conversion price of $8.302 per share and pre-funded warrants to purchase 190,795 shares of our common
stock, and (ii) warrants to purchase 1,384,722 shares of our common stock, immediately exercisable at $8.302 per share and expiring five
years from the date of issuance. In connection with the June 2025 financing, we issued to the placement agent and its designees placement
agent warrants to purchase an aggregate of 83,083 shares of common stock at an exercise price per share equal to $8.302. The placement
agent warrants are immediately exercisable and expire five years from the date of issuance.

Reverse Stock Split

We implemented a 1-for-28
reverse stock split of our outstanding common stock, which became effective on June 26, 2025, with the shares beginning trading on a
post-split basis on the Nasdaq Capital Market on June 27, 2025. As a result of the reverse stock split, every 28 shares of our issued
and outstanding common stock were automatically converted into 1 share of common stock, without any change in the par value per share.
No fractional shares were issued in the reverse stock split, and stockholders received a cash payment equal to the value of the fractional
share, based on the adjusted closing price on Nasdaq as of June 26, 2025. The share and per share information in this prospectus supplement
have been adjusted for the reverse stock split, however, have not been adjusted in information and documents incorporated by reference
prior to June 26, 2025.

Company Information

Our principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY 10019 and our telephone number is (646) 427-2727. Our website address is http://www.indaptusrx.com. The information contained on, or that can be accessed through, our website is neither a part of nor incorporated into this Registration Statement. We have included our website address in this Registration Statement solely as an inactive textual reference.

| 3 |

<div align